Synthesis and pharmacological activities of pyrazole derivatives: A review

K Karrouchi, S Radi, Y Ramli, J Taoufik, YN Mabkhot… - Molecules, 2018 - mdpi.com
Pyrazole and its derivatives are considered a pharmacologically important active scaffold
that possesses almost all types of pharmacological activities. The presence of this nucleus in …

[HTML][HTML] New agents for the treatment of drug-resistant Mycobacterium tuberculosis

DT Hoagland, J Liu, RB Lee, RE Lee - Advanced drug delivery reviews, 2016 - Elsevier
Inadequate dosing and incomplete treatment regimens, coupled with the ability of the
tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have …

A survey of the role of noncovalent sulfur interactions in drug design

BR Beno, KS Yeung, MD Bartberger… - Journal of medicinal …, 2015 - ACS Publications
Electron deficient, bivalent sulfur atoms have two areas of positive electrostatic potential, a
consequence of the low-lying σ* orbitals of the C–S bond that are available for interaction …

The therapeutic voyage of pyrazole and its analogs: a review

MF Khan, MM Alam, G Verma, W Akhtar… - European journal of …, 2016 - Elsevier
Pyrazole, a five membered heteroaromatic ring with two nitrogen atoms is of immense
significance. Presence of this nucleus in the pharmacological agents of diverse therapeutic …

Recent advances of pyrazole-containing derivatives as anti-tubercular agents

Z Xu, C Gao, QC Ren, XF Song, LS Feng… - European journal of …, 2017 - Elsevier
One-third of the world's population infected tuberculosis (TB), and more than 1 million
deaths annually. The co-infection between the mainly pathogen Mycobacterium tuberculosis …

Recent advancements in the development of anti-tuberculosis drugs

S Chetty, M Ramesh, A Singh-Pillay… - Bioorganic & medicinal …, 2017 - Elsevier
Modern chemotherapy has significantly improved patient outcomes against drug-sensitive
tuberculosis. However, the rapid emergence of drug-resistant tuberculosis, together with the …

Drug discovery in tuberculosis. New drug targets and antimycobacterial agents

A Campaniço, R Moreira, F Lopes - European journal of medicinal …, 2018 - Elsevier
Tuberculosis (TB) remains a major health problem worldwide. The infectious agent,
Mycobacterium tuberculosis, has a unique ability to survive within the host, alternating …

The tuberculosis drug discovery and development pipeline and emerging drug targets

K Mdluli, T Kaneko, A Upton - Cold Spring …, 2015 - perspectivesinmedicine.cshlp.org
The recent accelerated approval for use in extensively drug-resistant and multidrug-resistant-
tuberculosis (MDR-TB) of two first-in-class TB drugs, bedaquiline and delamanid, has …

Discovery of new diaryl ether inhibitors against Mycobacterium tuberculosis targeting the minor portal of InhA

M Chebaiki, E Delfourne, R Tamhaev, S Danoun… - European Journal of …, 2023 - Elsevier
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) affects 10 million people
each year and the emergence of resistant TB augurs for a growing incidence. In the last 60 …

Tuberculosis drug discovery: A decade of hit assessment for defined targets

S Oh, L Trifonov, VD Yadav, CE Barry III… - Frontiers in Cellular …, 2021 - frontiersin.org
More than two decades have elapsed since the publication of the first genome sequence of
Mycobacterium tuberculosis (Mtb) which, shortly thereafter, enabled methods to determine …